iBio updates corporate presentation; no specific material changes disclosed

iBio, Inc.

iBio furnished an updated corporate presentation dated October 2024, focused on precision antibody therapeutics powered by machine learning.
No new financial guidance, pipeline milestones, or operational metrics were provided in the 8-K filing.
The presentation is furnished under Regulation FD and not incorporated by reference into SEC filings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.